In 2026, the Global Opioid-Induced Constipation (OIC) Drugs Market is undergoing a significant transition from conventional rescue therapies (laxatives) toward targeted physiological solutions. As global healthcare systems refine pain management protocols, the focus has shifted toward Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs) that address the root cause of the condition without compromising the central analgesic efficacy of opioids. The market is also seeing the emergence of non-opioid acute analgesics (like suzetrigine) which, while reducing the future OIC patient pool, are currently driving current OIC stakeholders to innovate in "Digital-Therapeutic" co-prescriptions to ensure patient adherence.
Market Valuation & Forecast (2025–2036)
The Global Opioid-Induced Constipation (OIC) Drugs Market was valued at approximately USD 3.06 Billion in 2025. It is projected to reach USD 7.42 Billion by the year 2036, growing at a CAGR of 8.4% globally.
Segments Analysis
The market is characterized by a shift toward specialized pharmacological classes and patient-specific dosing forms.
| Category | Key Segments |
| By Drug Class | PAMORAs (Dominant - 72%+ share: Methylnaltrexone, Naloxegol, Naldemedine), Chloride Channel-2 Activators (Lubiprostone), Prokinetics/Serotonin Receptor Agonists, Laxatives (Bulk, Stimulant, Osmotic). |
| By Prescription Type | Prescription Drugs (90% share: Branded & Generic), Over-The-Counter (OTC) (Projected to grow at ~7.9% CAGR through 2031). |
| By Route of Administration | Oral (Largest share ~94%: Preferred for chronic use), Parenteral/Injectable (Highest growth in hospital settings for acute/post-surgical care). |
| By Patient Group | Non-Cancer Chronic Pain (Largest segment), Cancer-Related Pain/Palliative Care (Fastest growing at ~9.1% CAGR). |
| By Distribution Channel | Hospital Pharmacies (Dominant), Retail Pharmacies, Online Pharmacies (Fastest growth due to telehealth integration). |
Regional Analysis
-
North America: The dominant market (~44% share). Leadership is sustained by high opioid prescription rates (approx. 46 per 100 people in the U.S.), advanced diagnostic awareness, and a robust reimbursement landscape for premium PAMORAs.
-
Europe: Focuses on integration within oncology palliative care. Germany and the UK are leading in the clinical adoption of oral naldemedine, supported by centralized healthcare guidelines.
-
Asia-Pacific: The fastest-growing region (CAGR ~9.0%+). Driven by a rapidly aging population in Japan and China, rising cancer prevalence, and increasing medical access in Southeast Asia.
-
LAMEA: A developing segment where urban urology and pain clinics in Brazil and Saudi Arabia are transitioning from traditional laxatives to targeted pharmacological interventions.
Top Key Players
-
Global Leaders: AstraZeneca plc, Bausch Health Companies Inc. (Salix Pharmaceuticals), Shionogi & Co., Ltd., Takeda Pharmaceutical Company Limited.
-
Strategic Manufacturers: Mallinckrodt Pharmaceuticals, Daiichi Sankyo Co., Ltd., Pfizer Inc., Ironwood Pharmaceuticals, RedHill Biopharma.
-
Emerging & Specialized: Theravance Biopharma, BioGaia Pharma (BGP345A pipeline), Lupin Ltd (Generics), Cumberland Pharmaceuticals, S.L.A. Pharma AG.
Porter’s Five Forces
-
Bargaining Power of Buyers (Moderate-High): Hospital formularies and insurance payers demand clear evidence of "Cost-Effectiveness" before moving patients from cheap laxatives to expensive PAMORAs.
-
Threat of New Entrants (Low-Moderate): High regulatory hurdles for controlled-substance-adjacent drugs; however, biosimilar and generic entries (e.g., Prucalopride) are increasing competition.
-
Bargaining Power of Suppliers (Moderate): Suppliers of active pharmaceutical ingredients (APIs) for quaternary amines have moderate leverage due to strict quality and purity standards.
-
Threat of Substitutes (Moderate): Emerging non-opioid analgesics (e.g., NaV1.8 inhibitors) threaten the long-term size of the OIC pool by reducing overall opioid reliance.
-
Competitive Rivalry (High): Intense competition between once-daily oral formulations; players are now competing on "Patient-Reported Outcomes" (PROs) and quality-of-life metrics.
SWOT Analysis
-
Strengths: High clinical unmet need (40-80% of opioid users experience OIC); PAMORAs do not interfere with pain relief.
-
Weaknesses: High cost of branded therapies compared to OTC laxatives; patient reluctance to discuss bowel issues.
-
Opportunities: Combination Opioid-PAMORA pills to improve compliance; AI-driven diagnostic apps to flag OIC early in the prescription cycle.
-
Threats: Tighter opioid prescribing guidelines reducing the total addressable market; expansion of the medical cannabis market as an opioid alternative.
Trend Analysis 2026
-
Digital-Therapeutic Integration: Prescriptions are increasingly paired with mobile apps that track bowel movements and offer real-time dietary advice to supplement drug therapy.
-
Pediatric Label Extensions: Increased focus on treating OIC in pediatric oncology and chronic pain populations with weight-adjusted PAMORA dosing.
-
The "Shift to Oral": Injectable methylnaltrexone remains standard in hospitals, but the 2026 market is seeing a massive surge in oral-stable formulations for the transition to home-based palliative care.
Drivers & Challenges
-
Driver: Rising Global Cancer Burden: Increasing survivorship and long-term palliative care needs are driving sustained demand for OIC management.
-
Driver: Aging Geriatric Demographic: Older adults are more susceptible to both chronic pain and the gastrointestinal side effects of opioids.
-
Challenge: Social Stigma: The dual stigma of opioid use and constipation often leads to under-reporting, delaying effective treatment until symptoms are severe.
-
Challenge: Regulatory Scrutiny: Increased monitoring of opioid-related drugs by the FDA and EMA can prolong the clinical trial and approval process for new candidates.
Value Chain Analysis
-
R&D & Molecule Discovery: Focus on gut-restricted receptor blockade that cannot cross the blood-brain barrier.
-
Specialized API Manufacturing: Production of quaternary amines and pegylated derivatives.
-
Clinical Validation: Conducting "Real-World Evidence" studies to prove reduction in hospital readmission rates.
-
Prescription & Dispensing: Integration into Electronic Health Records (EHR) to prompt OIC assessment at the point of opioid prescription.
Quick Recommendations for Stakeholders
-
For Manufacturers: Focus on Combo-Formulations. Developing fixed-dose combinations of an opioid with a PAMORA could revolutionize the market by preventing OIC before it starts.
-
For Hospital Administrators: Implement Automated Screening Protocols. Incorporating OIC screening questions into standard patient rounds for those on high-dose opioids can significantly improve patient satisfaction and outcomes.
-
For Investors: Monitor the Cancer-Palliative Segment. While the non-cancer opioid market may shrink due to regulation, the cancer-related pain market remains a stable, high-growth area for OIC therapeutics.
1. Market Overview of Opioid Induced Constipation (OIC) Drugs
1.1 Opioid Induced Constipation (OIC) Drugs Market Overview
1.1.1 Opioid Induced Constipation (OIC) Drugs Product Scope
1.1.2 Market Status and Outlook
1.2 Opioid Induced Constipation (OIC) Drugs Market Size by Regions:
1.3 Opioid Induced Constipation (OIC) Drugs Historic Market Size by Regions
1.4 Opioid Induced Constipation (OIC) Drugs Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Opioid Induced Constipation (OIC) Drugs Sales Market by Type
2.1 Global Opioid Induced Constipation (OIC) Drugs Historic Market Size by Type
2.2 Global Opioid Induced Constipation (OIC) Drugs Forecasted Market Size by Type
2.3 Lubiprostone
2.4 Methyl Naltrexone Bromide
2.5 Naldemedine
2.6 Alvimopan
2.7 Others
2.8 Market by Prescription Type
2.9 Generic and Branded Prescribed Drugs
2.10 Over The Counter Drugs
3. Covid-19 Impact Opioid Induced Constipation (OIC) Drugs Sales Market by Application
3.1 Global Opioid Induced Constipation (OIC) Drugs Historic Market Size by Application
3.2 Global Opioid Induced Constipation (OIC) Drugs Forecasted Market Size by Application
3.3 Hospital Pharmacies
3.4 Retail Pharmacies
3.5 Online Pharmacies
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Opioid Induced Constipation (OIC) Drugs Production Capacity Market Share by Manufacturers
4.2 Global Opioid Induced Constipation (OIC) Drugs Revenue Market Share by Manufacturers
4.3 Global Opioid Induced Constipation (OIC) Drugs Average Price by Manufacturers
5. Company Profiles and Key Figures in Opioid Induced Constipation (OIC) Drugs Business
5.1 Ironwood Pharmaceuticals Inc
5.1.1 Ironwood Pharmaceuticals Inc Company Profile
5.1.2 Ironwood Pharmaceuticals Inc Opioid Induced Constipation (OIC) Drugs Product Specification
5.1.3 Ironwood Pharmaceuticals Inc Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.2 Daiichi Sankyo Co Ltd
5.2.1 Daiichi Sankyo Co Ltd Company Profile
5.2.2 Daiichi Sankyo Co Ltd Opioid Induced Constipation (OIC) Drugs Product Specification
5.2.3 Daiichi Sankyo Co Ltd Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.3 Pfizer
5.3.1 Pfizer Company Profile
5.3.2 Pfizer Opioid Induced Constipation (OIC) Drugs Product Specification
5.3.3 Pfizer Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.4 Progenics Pharmaceuticals Inc
5.4.1 Progenics Pharmaceuticals Inc Company Profile
5.4.2 Progenics Pharmaceuticals Inc Opioid Induced Constipation (OIC) Drugs Product Specification
5.4.3 Progenics Pharmaceuticals Inc Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.5 Shionogi & Co. Ltd
5.5.1 Shionogi & Co. Ltd Company Profile
5.5.2 Shionogi & Co. Ltd Opioid Induced Constipation (OIC) Drugs Product Specification
5.5.3 Shionogi & Co. Ltd Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.6 Allergan Plc
5.6.1 Allergan Plc Company Profile
5.6.2 Allergan Plc Opioid Induced Constipation (OIC) Drugs Product Specification
5.6.3 Allergan Plc Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.7 Nektar Therapeutics
5.7.1 Nektar Therapeutics Company Profile
5.7.2 Nektar Therapeutics Opioid Induced Constipation (OIC) Drugs Product Specification
5.7.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.8 Purdue Pharma
5.8.1 Purdue Pharma Company Profile
5.8.2 Purdue Pharma Opioid Induced Constipation (OIC) Drugs Product Specification
5.8.3 Purdue Pharma Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.9 S.L.A. Pharma AG
5.9.1 S.L.A. Pharma AG Company Profile
5.9.2 S.L.A. Pharma AG Opioid Induced Constipation (OIC) Drugs Product Specification
5.9.3 S.L.A. Pharma AG Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.10 Mundipharma International Limited
5.10.1 Mundipharma International Limited Company Profile
5.10.2 Mundipharma International Limited Opioid Induced Constipation (OIC) Drugs Product Specification
5.10.3 Mundipharma International Limited Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.11 Ono Pharmaceutical Co. Ltd
5.11.1 Ono Pharmaceutical Co. Ltd Company Profile
5.11.2 Ono Pharmaceutical Co. Ltd Opioid Induced Constipation (OIC) Drugs Product Specification
5.11.3 Ono Pharmaceutical Co. Ltd Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.12 Takeda Pharmaceutical Company Limited
5.12.1 Takeda Pharmaceutical Company Limited Company Profile
5.12.2 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drugs Product Specification
5.12.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.13 Theravance Biopharma Inc
5.13.1 Theravance Biopharma Inc Company Profile
5.13.2 Theravance Biopharma Inc Opioid Induced Constipation (OIC) Drugs Product Specification
5.13.3 Theravance Biopharma Inc Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.14 Valeant Pharmaceuticals International
5.14.1 Valeant Pharmaceuticals International Company Profile
5.14.2 Valeant Pharmaceuticals International Opioid Induced Constipation (OIC) Drugs Product Specification
5.14.3 Valeant Pharmaceuticals International Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.15 Cosmo Pharmaceuticals SA
5.15.1 Cosmo Pharmaceuticals SA Company Profile
5.15.2 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drugs Product Specification
5.15.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.16 Daewoong Pharmaceutical
5.16.1 Daewoong Pharmaceutical Company Profile
5.16.2 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drugs Product Specification
5.16.3 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.17 C.B. Fleet Company
5.17.1 C.B. Fleet Company Company Profile
5.17.2 C.B. Fleet Company Opioid Induced Constipation (OIC) Drugs Product Specification
5.17.3 C.B. Fleet Company Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
5.18 Sucampo Pharmaceuticals
5.18.1 Sucampo Pharmaceuticals Company Profile
5.18.2 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Product Specification
5.18.3 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drugs Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Opioid Induced Constipation (OIC) Drugs Market Size
6.2 North America Opioid Induced Constipation (OIC) Drugs Key Players in North America
6.3 North America Opioid Induced Constipation (OIC) Drugs Market Size by Type
6.4 North America Opioid Induced Constipation (OIC) Drugs Market Size by Application
7. East Asia
7.1 East Asia Opioid Induced Constipation (OIC) Drugs Market Size
7.2 East Asia Opioid Induced Constipation (OIC) Drugs Key Players in North America
7.3 East Asia Opioid Induced Constipation (OIC) Drugs Market Size by Type
7.4 East Asia Opioid Induced Constipation (OIC) Drugs Market Size by Application
8. Europe
8.1 Europe Opioid Induced Constipation (OIC) Drugs Market Size
8.2 Europe Opioid Induced Constipation (OIC) Drugs Key Players in North America
8.3 Europe Opioid Induced Constipation (OIC) Drugs Market Size by Type
8.4 Europe Opioid Induced Constipation (OIC) Drugs Market Size by Application
9. South Asia
9.1 South Asia Opioid Induced Constipation (OIC) Drugs Market Size
9.2 South Asia Opioid Induced Constipation (OIC) Drugs Key Players in North America
9.3 South Asia Opioid Induced Constipation (OIC) Drugs Market Size by Type
9.4 South Asia Opioid Induced Constipation (OIC) Drugs Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Opioid Induced Constipation (OIC) Drugs Market Size
10.2 Southeast Asia Opioid Induced Constipation (OIC) Drugs Key Players in North America
10.3 Southeast Asia Opioid Induced Constipation (OIC) Drugs Market Size by Type
10.4 Southeast Asia Opioid Induced Constipation (OIC) Drugs Market Size by Application
11. Middle East
11.1 Middle East Opioid Induced Constipation (OIC) Drugs Market Size
11.2 Middle East Opioid Induced Constipation (OIC) Drugs Key Players in North America
11.3 Middle East Opioid Induced Constipation (OIC) Drugs Market Size by Type
11.4 Middle East Opioid Induced Constipation (OIC) Drugs Market Size by Application
12. Africa
12.1 Africa Opioid Induced Constipation (OIC) Drugs Market Size
12.2 Africa Opioid Induced Constipation (OIC) Drugs Key Players in North America
12.3 Africa Opioid Induced Constipation (OIC) Drugs Market Size by Type
12.4 Africa Opioid Induced Constipation (OIC) Drugs Market Size by Application
13. Oceania
13.1 Oceania Opioid Induced Constipation (OIC) Drugs Market Size
13.2 Oceania Opioid Induced Constipation (OIC) Drugs Key Players in North America
13.3 Oceania Opioid Induced Constipation (OIC) Drugs Market Size by Type
13.4 Oceania Opioid Induced Constipation (OIC) Drugs Market Size by Application
14. South America
14.1 South America Opioid Induced Constipation (OIC) Drugs Market Size
14.2 South America Opioid Induced Constipation (OIC) Drugs Key Players in North America
14.3 South America Opioid Induced Constipation (OIC) Drugs Market Size by Type
14.4 South America Opioid Induced Constipation (OIC) Drugs Market Size by Application
15. Rest of the World
15.1 Rest of the World Opioid Induced Constipation (OIC) Drugs Market Size
15.2 Rest of the World Opioid Induced Constipation (OIC) Drugs Key Players in North America
15.3 Rest of the World Opioid Induced Constipation (OIC) Drugs Market Size by Type
15.4 Rest of the World Opioid Induced Constipation (OIC) Drugs Market Size by Application
16 Opioid Induced Constipation (OIC) Drugs Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter’s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Segments Analysis
The market is characterized by a shift toward specialized pharmacological classes and patient-specific dosing forms.
| Category | Key Segments |
| By Drug Class | PAMORAs (Dominant - 72%+ share: Methylnaltrexone, Naloxegol, Naldemedine), Chloride Channel-2 Activators (Lubiprostone), Prokinetics/Serotonin Receptor Agonists, Laxatives (Bulk, Stimulant, Osmotic). |
| By Prescription Type | Prescription Drugs (90% share: Branded & Generic), Over-The-Counter (OTC) (Projected to grow at ~7.9% CAGR through 2031). |
| By Route of Administration | Oral (Largest share ~94%: Preferred for chronic use), Parenteral/Injectable (Highest growth in hospital settings for acute/post-surgical care). |
| By Patient Group | Non-Cancer Chronic Pain (Largest segment), Cancer-Related Pain/Palliative Care (Fastest growing at ~9.1% CAGR). |
| By Distribution Channel | Hospital Pharmacies (Dominant), Retail Pharmacies, Online Pharmacies (Fastest growth due to telehealth integration). |
Regional Analysis
-
North America: The dominant market (~44% share). Leadership is sustained by high opioid prescription rates (approx. 46 per 100 people in the U.S.), advanced diagnostic awareness, and a robust reimbursement landscape for premium PAMORAs.
-
Europe: Focuses on integration within oncology palliative care. Germany and the UK are leading in the clinical adoption of oral naldemedine, supported by centralized healthcare guidelines.
-
Asia-Pacific: The fastest-growing region (CAGR ~9.0%+). Driven by a rapidly aging population in Japan and China, rising cancer prevalence, and increasing medical access in Southeast Asia.
-
LAMEA: A developing segment where urban urology and pain clinics in Brazil and Saudi Arabia are transitioning from traditional laxatives to targeted pharmacological interventions.
Top Key Players
-
Global Leaders: AstraZeneca plc, Bausch Health Companies Inc. (Salix Pharmaceuticals), Shionogi & Co., Ltd., Takeda Pharmaceutical Company Limited.
-
Strategic Manufacturers: Mallinckrodt Pharmaceuticals, Daiichi Sankyo Co., Ltd., Pfizer Inc., Ironwood Pharmaceuticals, RedHill Biopharma.
-
Emerging & Specialized: Theravance Biopharma, BioGaia Pharma (BGP345A pipeline), Lupin Ltd (Generics), Cumberland Pharmaceuticals, S.L.A. Pharma AG.
